| 9.24 -0.42 (-4.35%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 11.66 | 1-year : | 13.62 |
| Resists | First : | 9.98 | Second : | 11.66 |
| Pivot price | 8.71  |
|||
| Supports | First : | 8.14 | Second : | 7 |
| MAs | MA(5) : | 8.98 |
MA(20) : | 8.45 |
| MA(100) : | 9.42  |
MA(250) : | 10.79 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 77.1 |
D(3) : | 70.8 |
| RSI | RSI(14): 58.3 |
|||
| 52-week | High : | 18.29 | Low : | 6.57 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ETNB ] has closed below upper band by 21.2%. Bollinger Bands are 20.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.86 - 9.91 | 9.91 - 9.94 |
| Low: | 9.08 - 9.13 | 9.13 - 9.17 |
| Close: | 9.16 - 9.24 | 9.24 - 9.31 |
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Fri, 26 Jul 2024
Ameritas Investment Partners Inc. Has $92,000 Holdings in 89bio, Inc. (NASDAQ:ETNB) - Defense World
Wed, 24 Jul 2024
89bio (NASDAQ:ETNB) Shares Up 7.6% - MarketBeat
Wed, 24 Jul 2024
Swiss National Bank Has $1.71 Million Position in 89bio, Inc. (NASDAQ:ETNB) - Defense World
Mon, 22 Jul 2024
89bio (NASDAQ:ETNB) Trading Down 3.4% - MarketBeat
Thu, 23 May 2024
89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy (NASDAQ:ETNB) - Seeking Alpha
Wed, 03 Apr 2024
89bio CEO Rohan Palekar trades over $620k in company stock - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 98 (M) |
| Shares Float | 70 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 107.3 (%) |
| Shares Short | 6,420 (K) |
| Shares Short P.Month | 10,580 (K) |
| EPS | -2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.36 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -21 % |
| Return on Equity (ttm) | -34.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.83 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -139 (M) |
| Levered Free Cash Flow | -84 (M) |
| PE Ratio | -4.62 |
| PEG Ratio | -0.4 |
| Price to Book value | 1.72 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.55 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|